Has Mitul Gandhi, MD received payments from drug or device companies?

Yes. Drug and device makers reported $6,948,118 in general payments to Mitul Gandhi, MD across 1,864 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Mitul Gandhi, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Mitul Gandhi, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Mitul Gandhi, MD

Hematology & Oncology · Manassas, VANPI 1639379308

Payments from drug & device makers

$6,948,118in general payments, 2019–2025

Across 1,864 payments — averaging $3727.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Genentech, Inc.$1.9M
AstraZeneca$859K
AbbVie$737K
Beigene, Ltd.$538K
Epizyme, Inc.$498K
Janssen Research & Development, LLC$462K
plus $1.9M from 40 others

$14,280in research payments, 2019–2025

Across 12 payments — averaging $1190.03 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

F. Hoffmann-la Roche AG$9K
Pfizer$4K
Eli Lilly$758
AbbVie$148

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Genentech, Inc.	519	$1,911,375
AstraZeneca	16	$858,625
AbbVie	71	$736,977
Beigene, Ltd.	44	$538,297
Epizyme, Inc.	333	$497,602
Janssen Research & Development, LLC	305	$462,128
Seagen Inc.	259	$453,489
TG Therapeutics, Inc.	60	$304,554
Novartis	21	$272,262
ADC Therapeutics America, Inc.	30	$244,682
Eli Lilly	14	$234,719
Karyopharm Therapeutics Inc.	42	$116,942
Beone Medicines Ltd.	2	$96,416
Sumitomo Pharma America, Inc.	14	$80,234
Morphosys AG	37	$65,529
Pfizer	33	$34,262
E.r. Squibb & Sons, L.L.C.	2	$20,023
Incyte Corporation	15	$14,152
GSK	3	$1,877
Morphosys, US Inc.	1	$956
Johnson & Johnson(2 entities)	5	$846
Janssen Scientific Affairs, LLC	1	$818
F. Hoffmann-la Roche AG	1	$370
Exelixis Inc.	1	$100
Beigene USA, Inc.	4	$91
Bioprotect Medical, Inc.	1	$85
Merck	4	$65
Genmab U.S., Inc.	2	$61
Gilead(2 entities)	3	$57
Takeda Pharmaceuticals U.S.A., Inc.	2	$56
Servier Pharmaceuticals LLC	2	$48
Eisai Inc.	2	$47
Sanofi	1	$46
Ipsen Biopharmaceuticals, Inc	2	$43
Regeneron Healthcare Solutions, Inc.	1	$37
Iovance Biotherapeutics, Inc.	1	$36
Rigel Pharmaceuticals, Inc.	1	$27
Astellas Pharma US Inc	1	$25
Bristol Myers Squibb	1	$24
Beone Medicines USA, Inc.	1	$23
Geron Corporation	1	$21
Sun Pharmaceutical Industries Inc.	1	$20
Medtronic	1	$19
Genentech USA, Inc.	1	$19
Blueprint Medicines Corporation	1	$18
Bayer	1	$15

How this compares

$6,948,118 in reported general payments places this provider in the 95th percentile of 293 hematology & oncology providers in Virginia.

See all hematology & oncology providers in Virginia →

Medicare billing

Part B allowed, 2024

$2,776,371

Medicare patients

598

Services billed

126,683

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other hematology & oncology in Manassas

Craig PortellCharlottesville$12.9M
Amanda Gillespie-TwardyRoanoke$12.2M
Sekwon JangFairfax$11.8M
Mark FlemingHampton$10M
Mark KochenderferRoanoke$8.6M
Michael DansoNorfolk$6.9M
Jerome GoldschmidtChristiansburg$6.5M
William IrvinMidlothian$4.3M
Lakshminarayanan NandagopalFredericksburg$3.9M
Neelima DenduluriArlington$3.1M

See the full list for Virginia →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →